Trials / Terminated
TerminatedNCT04864782
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
A Study of QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of PD-1 Inhibitor (QL1604) plus chemotherapy in patients with Stage IV, recurrent, or metastatic cervical cancer. Possible chemotherapy regimens include: paclitaxel plus cisplatin and paclitaxel plus carboplatin.
Detailed description
The study will be conducted in 2 parts.The first stage is a single-arm clinical trial, and the second stage is a controlled clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QL1604 | Intravenous Infusion |
| DRUG | Paclitaxel injection | Intravenous Infusion |
| DRUG | Cisplatin/Carboplatin | Intravenous Infusion |
Timeline
- Start date
- 2020-09-23
- Primary completion
- 2022-09-30
- Completion
- 2023-11-01
- First posted
- 2021-04-29
- Last updated
- 2024-01-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04864782. Inclusion in this directory is not an endorsement.